Renovaro Management
Management criteria checks 1/4
Renovaro's CEO is David Weinstein, appointed in Oct 2024, has a tenure of less than a year. directly owns 0.16% of the company’s shares, worth $129.75K. The average tenure of the management team and the board of directors is 1.3 years and 3.3 years respectively.
Key information
David Weinstein
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 1.3yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Enochian stock climbs on US patent for oncology platform
Oct 17Enochian BioSciences discovers two sets of altered animal data in two of its studies
Jul 01Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?
Jun 28
Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Feb 20Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Oct 30Enochian Biosciences: A Follow Through For An HIV Cure
Jun 26Enochian Biosciences shares skyrocket after FDA accepts Pre-IND request for HIV treatment
Jun 14Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?
Feb 14CEO
David Weinstein (64 yo)
less than a year
Tenure
Mr. David H. Weinstein, also known as David, is CEO & Director of Renovaro Inc. from October 14, 2024. Mr. Weinstein has extensive experience with U.S. securities and investment banking firms. He has been...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim Chief Financial Officer | less than a year | US$330.33k | no data | |
| COO and Executive VP for Research & Development | 2yrs | US$430.29k | 0% $ 0 | |
| CEO & Director | less than a year | no data | 0.16% $ 129.7k | |
| Co-Founder & Inventor | no data | no data | 11.12% $ 9.2m | |
| Senior Vice President for Clinical Operations | 2.6yrs | no data | no data |
1.3yrs
Average Tenure
63yo
Average Age
Experienced Management: RENB's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | 0.16% $ 129.7k | |
| Independent Director | less than a year | no data | no data | |
| Member of Respiratory Diseases Scientific Advisory Board | 3.3yrs | no data | no data | |
| Member of HBV Scientific Advisory Board | 3.3yrs | no data | no data | |
| Chairperson of HBV Cure Scientific Advisory Board | 4.3yrs | US$129.74k | 0% $ 0 | |
| Member of HBV Scientific Advisory Board | 4.3yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Chairman of HIV Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of HIV Scientific Advisory Board | 6.8yrs | no data | no data | |
| Member of HBV Scientific Advisory Board | 4.3yrs | no data | no data | |
| Chairman of Scientific Advisory Board | less than a year | no data | no data |
3.3yrs
Average Tenure
72yo
Average Age
Experienced Board: RENB's board of directors are considered experienced (3.3 years average tenure).